Drugs / Hydroxycamptothecin
Hydroxycamptothecin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT07424287 Comparator | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02755311 Comparator | Mar 2014 → Jun 2016 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroxycamptothecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07424287 ↗ |
| Known as | (s)-10-hydroxycamptothecin | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Known as | 10-hcpt | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Known as | 10-hydroxy camptothecin | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Known as | 10-hydroxycamptothecine | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Known as | Irinotecan related compound a | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Known as | NSC-107124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL273862 ↗ |
| Modality | Small molecule | — CHEMBL273862 ↗ |